A randomized study of two different schedules of methyl CCNU, 5‐FU and vincristine for metastatic colorectal carcinoma Academic Article Article uri icon


MeSH Major

  • Acquired Immunodeficiency Syndrome


  • Sixty-seven patients with measurable colorectal carcinoma were randomized to receive two different schedules of Methyl CCNU, 5-FU and Vincristine (MOF). The treatment schedule consisted of Methyl CCNU 150 mg/m2 po q 70 days, 5-FU 300 mg/m2 iv for 5 consecutive days q 35 days, and Vincristine 1 mg/m2 IV q 35 days. The same total dose was used in each arm; in MOF A, the Methyl CCNU was given on day 1, while in MOF B, the Methyl CCNU was divided and given over 5 consecutive days. In MOF A, there was a 10% partial response rate and a 10% minor response rate. In MOF B, the partial response rate was 12% and the minor response rate was 21%. This difference is not statistically significant, but the patients in MOF B experienced less gastrointestinal toxicity (p less than .001).

publication date

  • January 1979



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1002/1097-0142(197901)43:1<78::AID-CNCR2820430111>3.0.CO;2-H

PubMed ID

  • 367575

Additional Document Info

start page

  • 78

end page

  • 82


  • 43


  • 1